GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences return on equity (ROE)

Gilead Sciences's return on equity is 35.38%: net income of 4.61B USD over the last twelve months on shareholders' equity of 13.04B USD.

Today
35.38%
Average, 5 years
24.04%
Low, 5 years
0.62%
High, 5 years
44.26%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 4.61B ÷ 13.04B = 35.38%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is Gilead Sciences's return on equity so high?

Net margin
28.9%
profit on each dollar of sales
Asset turnover
0.50×
sales on each dollar of assets
Equity multiplier
2.60×
assets on each dollar of equity
Return on equity
37.5%
FY2025
  • FY202528.9% × 0.50 × 2.60 = 37.5%
  • FY20241.7% × 0.49 × 3.05 = 2.5%
  • FY202320.9% × 0.44 × 2.72 = 24.8%
  • FY202216.8% × 0.43 × 2.97 = 21.6%
  • FY202122.8% × 0.40 × 3.23 = 29.5%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today35.38%4.61B13.04B
FY202531 Dec 202537.49%8.51B22.70B
FY202431 Dec 20242.48%480.00M19.33B
FY202331 Dec 202324.81%5.67B22.83B
FY202231 Dec 202221.62%4.59B21.24B
FY202131 Dec 202129.43%6.20B21.07B
FY202031 Dec 20200.68%123.00M18.20B
FY201931 Dec 201923.81%5.36B22.53B
FY201831 Dec 201825.53%5.46B21.39B
FY201731 Dec 201722.72%4.64B20.44B
FY201631 Dec 201671.41%13.49B18.89B
FY201531 Dec 201597.69%18.11B18.53B
FY201431 Dec 201478.17%12.06B15.43B
FY201331 Dec 201326.89%3.06B11.37B
FY201231 Dec 201227.67%2.57B9.30B
FY201131 Dec 201141.39%2.79B6.74B
FY201031 Dec 201049.28%2.89B5.86B
FY200931 Dec 200941.24%2.63B6.37B
FY200831 Dec 200846.12%1.97B4.27B
FY200731 Dec 200746.69%1.62B3.46B
FY200631 Dec 2006-65.54%-1.19B1.82B
FY200531 Dec 200526.88%813.91M3.03B
FY200431 Dec 200424.02%449.37M1.87B
FY200331 Dec 2003-7.18%-72.00M1.00B
FY200231 Dec 200212.62%72.10M571.34M
FY200131 Dec 200111.55%52.27M452.44M
FY200031 Dec 2000-16.17%-56.78M351.12M
FY199931 Dec 1999-22.37%-66.50M297.29M
FY199831 Dec 1998-13.43%-44.80M333.70M
FY199731 Dec 1997-22.98%-72.90M317.30M
FY199631 Dec 1996-7.44%-21.70M291.70M
FY199531 Dec 1995-18.09%-27.40M151.50M
FY199431 Dec 1994-36.35%-31.30M86.10M
FY199231 Dec 1992-10.11%-14.10M139.40M
FY199131 Dec 1991-4.26%-4.50M105.60M
FY199031 Dec 1990-39.22%-4.00M10.20M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Gilead Sciences's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.